WebHere we report on the discovery of a site-specific, covalently-pegylated IL-2 that has substantially improved pharmacologic properties over native IL-2 for expansion of Tregs. … WebTHOR-707 is a reprogrammed, site-directed, single pegylated, recombinant human IL-2 (rIL-2) variant that lacks binding affinity for the α chain of the IL-2 receptor. Because THOR …
Interim late-breaking clinical data validate not-alpha …
WebTHOR-707, the IL-2 variant moiety binds to dimers containing the IL-2 receptor beta and gamma chains (IL2Rbg; IL2Rbetagamma) on immune cells activating these cells and inducing their expansion. It also induces the expression of certain cytotoxic cytokines. WebAccueil / Essais cliniques / Etude de phase 2 multicentrique, non randomisée, en ouvert, à plusieurs cohortes évaluant le bénéfice clinique du SAR444245 (THOR-707) associé à d’autres thérapies anticancéreuses pour le traitement de patients atteints de cancer du poumon ou de mésothéliome pleural. synechiae uterine pregnancy what happens
5 takeaways from AACR, one of the year
WebSince it cannot bind to IL2Ra expressed on innate lymphoid cells in the vascular endothelium, THOR-707 prevents IL-2-mediated recruitment and activation of eosinophils, and inhibits the induction of eosinophil-mediated vascular leak syndrome (VLS). Pegylation also extends the half-life of THOR-707. Compared to recombinant IL-2, THOR-707 allows ... WebPart 2 patients (pts) received escalating doses of THOR-707 with pembrolizumab 200 mg IV (Cohort C) following a 3+3 DED to identify the MTD and/or RP2D of the combination. Conclusions THOR-707 demonstrated encouraging biomarker data analogous to the not-α IL-2 effect observed in preclinical models with no indicators of VLS in this ongoing trial. WebJul 1, 2024 · IL-2 displays a promising potential in the treatment of autoimmune diseases because of its ability to selectively promote T reg cells at low doses. Nevertheless, the clinical application of IL-2 faces a dilemma because of its paradoxical effects on inducing effector cells (i.e., T eff and NK cells) at high doses, as well as its short half-life, making it … synechiae without cells and flare